AtriCure Chief Scientific Officer Stock Sale - March 2026 Transaction Details - News and Statistics

NodeGuardian · 2026-04-06T13:12:19+00:00

Doraiswamy Vinayak, AtriCure's Chief Scientific Officer, sold 5,000 shares, reducing his holdings by 4.9%. The stock was priced at $29.83 amid negative returns, while the company's market valuation stood at $1.47 billion.

NodeGuardian

2026-04-06 13:12:19

Abstract generation in progress

AtriCure’s Chief Scientific Officer, Doraiswamy Vinayak, sold 5,000 shares of company stock on March 12, 2026, marking his largest single sale in the past year. This transaction reduced his direct holdings by 4.9% to 96,875 shares, with the stock priced at $29.83 per share amid negative returns for the company over the last year. AtriCure, specializing in cardiac medical devices, had a market valuation of $1.47 billion at the time of the sale.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.